For research teamsHelp me find a study
Back to all studies
Not recruitingEUCTR 2022-001151-16

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

SchizophreniaDrug

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What the source confirms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View the historical EU CTR record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
850
Sponsor
Cerevel Therapeutics, LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Bulgaria, Hungary
Age range
Not clearly listed
Official registry ID
EUCTR 2022-001151-16
Official title
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia

Check recruitment and locations

EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

View the historical EU CTR record (opens in a new tab)View the current CTIS record (opens in a new tab)
Current CTIS country statuses
Historical EU CTR country statuses

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 15 sites
  • Higya–DCC OOD — n/a
    Pazardzhik
    Country status: Not recruiting
  • Ambulatory - Group Practice for Specialized Psychiatric Care DATAMED — n/a
    Pleven
    Country status: Not recruiting
  • Medical Center Medconsult Pleven OOD — n/a
    Pleven
    Country status: Not recruiting
  • University Multiprofile Hospital For Active Treatment Dr. Georgi Stranski EAD — 1st Psychiatric Clinic, Department of General Psychiatry and Department of Acute Psychotic Disorders
    Pleven
    Country status: Not recruiting
  • MBAL Dr. Ivan Seliminski - Sliven AD — Clinical trials room
    Sliven
    Country status: Not recruiting
  • Alexandrovska University Hospital — First ward of the Clinic of Psychiatry
    Sofia
    Country status: Not recruiting
  • Diagnostic Consultative Center 14 Sofia EOOD — n/a
    Sofia
    Country status: Not recruiting
  • Mental Health Center Sofia EOOD — n/a
    Sofia
    Country status: Not recruiting
  • Outpatient clinic for group practice for specialized medical help - Psihea OOD — n/a
    Sofia
    Country status: Not recruiting
  • Medical Center Hera EOOD — n/a
    Sofiya
    Country status: Not recruiting
  • Medical Center Intermedica Ltd. — n/a
    Sofiya
    Country status: Not recruiting
  • Umbal - Prof. D-R Stoyan Kirkovich AD — Psychiatry Department
    Stara Zagora
    Country status: Not recruiting
  • Diagnostics-Consultancy Center Mladost M Varna OOD — n/a
    Varna
    Country status: Not recruiting
  • Center Za Psihichno Zdrave Veliko Tarnovo EOOD — Department of psychiatry for active treatment of severe psychotic disorders
    Veliko Tirnovo
    Country status: Not recruiting
  • Center For Mental Health Vratsa EOOD — Department of General Psychiatry
    Vratsa
    Country status: Not recruiting
Hungary · 3 sites
  • Semmelweis University — Pszichiátriai és Pszichoterápiás Klinika
    Budapest
    Country status: Not recruiting
  • Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz — Pszichiátriai, Mentálhigiénés és Addiktológiai Osztály
    Gyor
    Country status: Not recruiting
  • Bacs-Kiskun Varmegyei Oktatokorhaz — Pszichiátriai Osztály
    Kalocsa
    Country status: Not recruiting

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: EUCTR 2022-001151-16. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Is this study recruiting?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
Not recruitingEUCTR 2008-002676-10

A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Drug study icon
Not recruitingEUCTR 2008-002699-83

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.